Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis

Juliana H VanderPluym, Rashmi B Halker Singh, Meritxell Urtecho, Allison S Morrow, Tarek Nayfeh, Victor D Torres Roldan, Magdoleen H Farah, Bashar Hasan, Samer Saadi, Sahrish Shah, Rami Abd-Rabu, Lubna Daraz, Larry J Prokop, Mohammad Hassan Murad, Zhen Wang, Juliana H VanderPluym, Rashmi B Halker Singh, Meritxell Urtecho, Allison S Morrow, Tarek Nayfeh, Victor D Torres Roldan, Magdoleen H Farah, Bashar Hasan, Samer Saadi, Sahrish Shah, Rami Abd-Rabu, Lubna Daraz, Larry J Prokop, Mohammad Hassan Murad, Zhen Wang

Abstract

Importance: Migraine is common and can be associated with significant morbidity, and several treatment options exist for acute therapy.

Objective: To evaluate the benefits and harms associated with acute treatments for episodic migraine in adults.

Data sources: Multiple databases from database inception to February 24, 2021.

Study selection: Randomized clinical trials and systematic reviews that assessed effectiveness or harms of acute therapy for migraine attacks.

Data extraction and synthesis: Independent reviewers selected studies and extracted data. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction or by using a fixed-effect model based on the Mantel-Haenszel method if the number of studies was small.

Main outcomes and measures: The main outcomes included pain freedom, pain relief, sustained pain freedom, sustained pain relief, and adverse events. The strength of evidence (SOE) was graded with the Agency for Healthcare Research and Quality Methods Guide for Effectiveness and Comparative Effectiveness Reviews.

Findings: Evidence on triptans and nonsteroidal anti-inflammatory drugs was summarized from 15 systematic reviews. For other interventions, 115 randomized clinical trials with 28 803 patients were included. Compared with placebo, triptans and nonsteroidal anti-inflammatory drugs used individually were significantly associated with reduced pain at 2 hours and 1 day (moderate to high SOE) and increased risk of mild and transient adverse events. Compared with placebo, calcitonin gene-related peptide receptor antagonists (low to high SOE), lasmiditan (5-HT1F receptor agonist; high SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), acetaminophen (moderate SOE), antiemetics (low SOE), butorphanol (low SOE), and tramadol in combination with acetaminophen (low SOE) were significantly associated with pain reduction and increase in mild adverse events. The findings for opioids were based on low or insufficient SOE. Several nonpharmacologic treatments were significantly associated with improved pain, including remote electrical neuromodulation (moderate SOE), transcranial magnetic stimulation (low SOE), external trigeminal nerve stimulation (low SOE), and noninvasive vagus nerve stimulation (moderate SOE). No significant difference in adverse events was found between nonpharmacologic treatments and sham.

Conclusions and relevance: There are several acute treatments for migraine, with varying strength of supporting evidence. Use of triptans, nonsteroidal anti-inflammatory drugs, acetaminophen, dihydroergotamine, calcitonin gene-related peptide antagonists, lasmiditan, and some nonpharmacologic treatments was associated with improved pain and function. The evidence for many other interventions, including opioids, was limited.

Conflict of interest statement

Conflict of Interest Disclosures: Dr VanderPluym reports consulting for Teva and receiving a research grant from Amgen. Dr Halker Singh reports consulting for Teva and Impel. No other disclosures were reported.

Figures

Figure 1.. Selection of Trials for Inclusion…
Figure 1.. Selection of Trials for Inclusion in the Review and Meta-analysis
NSAIDs indicates nonsteroidal anti-inflammatory drugs. aOther sources include reference mining of the included studies, gray literature search, and the technical experts panel. bThe purpose of using these systematic reviews and clinical trial registries was to identify relevant studies that may have been missed in the database search and in other sources. The studies found matched those that were already included, and no additional studies were identified through existing systematic reviews and clinical trial registries.
Figure 2.. Findings of Meta-analysis of Calcitonin…
Figure 2.. Findings of Meta-analysis of Calcitonin Gene-Related Peptide Receptor Antagonists on Pain and Function Measured as Binary Outcomes for Episodic Migraine in Adults
eTable 3 in the Supplement lists definitions of outcomes. eTable 6 in the Supplement lists definitions of strength of evidence (SOE) and approaches used to grade SOE. RCT indicates randomized clinical trial; RR, relative risk.
Figure 3.. Findings of Meta-analysis of 5-HT…
Figure 3.. Findings of Meta-analysis of 5-HT1F Receptor Agonists on Pain and Function Measured as Binary Outcomes for Episodic Migraine in Adults
eTable 3 in the Supplement lists definitions of outcomes. eTable 6 in the Supplement lists definitions of strength of evidence (SOE) and approaches used to grade SOE. RCT indicates randomized clinical trial; RR, relative risk.
Figure 4.. Findings of Meta-analysis of Antiemetics…
Figure 4.. Findings of Meta-analysis of Antiemetics on Pain and Function Measured as Binary Outcomes for Episodic Migraine in Adults
eTable 3 in the Supplement lists definitions of outcomes. eTable 6 in the Supplement lists definitions of strength of evidence (SOE) and approaches used to grade SOE. RCT indicates randomized clinical trial; RR, relative risk.

References

    1. GBD 2016 Headache Collaborators . Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-976. doi:10.1016/S1474-4422(18)30322-3
    1. Vos T, Lim SS, Abbafati C, et al. . Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9
    1. Headache Classification Committee of the International Headache Society (IHS): the International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
    1. Charleston IV L, Burke JF. Do racial/ethnic disparities exist in recommended migraine treatments in US ambulatory care? Cephalalgia. 2018;38(5):876-882. doi:10.1177/0333102417716933
    1. Sterne JAC, Savović J, Page MJ, et al. . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
    1. Viswanathan M, Patnode CD, Berkman ND, et al. . Recommendations for assessing the risk of bias in systematic reviews of health-care interventions. J Clin Epidemiol. 2018;97:26-34. doi:10.1016/j.jclinepi.2017.12.004
    1. Shea BJ, Grimshaw JM, Wells GA, et al. . Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. doi:10.1186/1471-2288-7-10
    1. Li T, Yu T, Hawkins BS, Dickersin K. Design, analysis, and reporting of crossover trials for inclusion in a meta-analysis. PLoS One. 2015;10(8):e0133023. doi:10.1371/journal.pone.0133023
    1. Röver C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. BMC Med Res Methodol. 2015;15:99. doi:10.1186/s12874-015-0091-1
    1. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality; 2014.
    1. Ashcroft DM, Millson D. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf. 2004;13(2):73-82. doi:10.1002/pds.890
    1. Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev. 2014;2014(5):CD008616.
    1. Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia. 2001;21(2):129-136. doi:10.1046/j.1468-2982.2001.00169.x
    1. Poolsup N, Leelasangaluk V, Jittangtrong J, Rithlamlert C, Ratanapantamanee N, Khanthong M. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J Clin Pharm Ther. 2005;30(6):521-532. doi:10.1111/j.1365-2710.2005.00677.x
    1. Chen L-C, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache. 2007;47(8):1169-1177. doi:10.1111/j.1526-4610.2007.00884.x
    1. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;(2):CD008615. doi:10.1002/14651858.CD008615.pub2
    1. Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;(2):CD009665. doi:10.1002/14651858.CD009665
    1. Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;(4):CD008783. doi:10.1002/14651858.CD008783.pub3
    1. Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;2013(4):CD008039. doi:10.1002/14651858.CD008039.pub3
    1. Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;(4):CD008041. doi:10.1002/14651858.CD008041.pub3
    1. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev. 2016;4(4):CD008541. doi:10.1002/14651858.CD008541.pub3
    1. Croop R, Goadsby PJ, Stock DA, et al. . Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi:10.1016/S0140-6736(19)31606-X
    1. Lipton RB, Croop R, Stock EG, et al. . Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142-149. doi:10.1056/NEJMoa1811090
    1. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114-125. doi:10.1177/0333102413500727
    1. Voss T, Lipton RB, Dodick DW, et al. . A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36(9):887-898. doi:10.1177/0333102416653233
    1. Dodick DW, Lipton RB, Ailani J, et al. . Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230-2241. doi:10.1056/NEJMoa1813049
    1. Lipton RB, Dodick DW, Ailani J, et al. . Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887-1898. doi:10.1001/jama.2019.16711
    1. Brandes JL, Klise S, Krege JH, et al. . Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 2019;39(11):1343-1357. doi:10.1177/0333102419864132
    1. Färkkilä M, Diener H-C, Géraud G, et al. ; COL MIG-202 Study Group . Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405-413. doi:10.1016/S1474-4422(12)70047-9
    1. Ferrari MD, Färkkilä M, Reuter U, et al. ; European COL-144 Investigators . Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan: a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170-1178. doi:10.1177/0333102410375512
    1. Goadsby PJ, Wietecha LA, Dennehy EB, et al. . Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894-1904. doi:10.1093/brain/awz134
    1. Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group . Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222-e2232. doi:10.1212/WNL.0000000000006641
    1. Brandes JL, Klise S, Krege JH, et al. . Long-term safety and efficacy of lasmiditan for acute treatment of migraine: final results of the GLADIATOR study. Cephalalgia Rep. 2020;3. doi:10.1177/2515816320958176
    1. Ashina M, Reuter U, Smith T, et al. . Randomized, controlled trial of lasmiditan over four migraine attacks: findings from the CENTURION study. Cephalalgia. 2021;41(3):294-304. doi:10.1177/0333102421989232
    1. Knievel K, Buchanan AS, Lombard L, et al. . Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia. 2020;40(1):19-27. doi:10.1177/0333102419889350
    1. Amiri H, Ghodrati N, Nikuyeh M, Shams-Vahdati S, Jalilzadeh-Binazar M. Comparison of granisetron and metoclopramide in the treatment of pain and emesis in migraine patients: a randomized controlled trial study. Turk J Emerg Med. 2017;17(2):61-64. doi:10.1016/j.tjem.2016.12.004
    1. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med. 2002;23(2):141-148. doi:10.1016/S0736-4679(02)00502-4
    1. Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med. 1995;2(7):597-602. doi:10.1111/j.1553-2712.1995.tb03596.x
    1. Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia. 2005;25(3):199-204. doi:10.1111/j.1468-2982.2004.00840.x
    1. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995;26(5):541-546. doi:10.1016/S0196-0644(95)70001-3
    1. Corbo J, Esses D, Bijur PE, Iannaccone R, Gallagher EJ. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med. 2001;38(6):621-627. doi:10.1067/mem.2001.119424
    1. Dexter SL, Graham AN, Johnston ES, Ratcliffe DM, Wilkinson MI, Rose AJ. Double-blind controlled study of Paramax in the acute treatment of common and classical migraine. Br J Clin Pract. 1985;39(10):388-392.
    1. Doğan NO, Pekdemir M, Yılmaz S, et al. . Intravenous metoclopramide in the treatment of acute migraines: a randomized, placebo-controlled trial. Acta Neurol Scand. 2019;139(4):334-339. doi:10.1111/ane.13063
    1. Fernando T, Lumanauw DD, Youn S, et al. . Buccally absorbed vs intravenous prochlorperazine for treatment of migraines headaches. Acta Neurol Scand. 2019;140(1):72-77. doi:10.1111/ane.13104
    1. Friedman BW, Esses D, Solorzano C, et al. . A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008;52(4):399-406. doi:10.1016/j.annemergmed.2007.09.027
    1. Friedman BW, Mulvey L, Esses D, et al. . Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med. 2011;57(5):475-82.e1. doi:10.1016/j.annemergmed.2010.11.023
    1. Friedman BW, Cabral L, Adewunmi V, et al. . Diphenhydramine as adjuvant therapy for acute migraine: an emergency department–based randomized clinical trial. Ann Emerg Med. 2016;67(1):32-39.e3. doi:10.1016/j.annemergmed.2015.07.495
    1. Gaffigan ME, Bruner DI, Wason C, Pritchard A, Frumkin K; Intravenous Metoclopramide for Acute Migraine Therapy in the Emergency Department . A randomized controlled trial of intravenous haloperidol vs intravenous metoclopramide for acute migraine therapy in the emergency department. J Emerg Med. 2015;49(3):326-334. doi:10.1016/j.jemermed.2015.03.023
    1. Honkaniemi J, Liimatainen S, Rainesalo S, Sulavuori S. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache. 2006;46(5):781-787. doi:10.1111/j.1526-4610.2006.00438.x
    1. Jones EB, Gonzalez ER, Boggs JG, Grillo JA, Elswick RK Jr. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994;24(2):237-241. doi:10.1016/S0196-0644(94)70135-0
    1. Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med. 1996;14(3):262-264. doi:10.1016/S0735-6757(96)90171-0
    1. McEwen JI, O’Connor HM, Dinsdale HB. Treatment of migraine with intramuscular chlorpromazine. Ann Emerg Med. 1987;16(7):758-763. doi:10.1016/S0196-0644(87)80569-3
    1. Miller MA, Levsky ME, Enslow W, Rosin A. Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache. Am J Emerg Med. 2009;27(2):160-164. doi:10.1016/j.ajem.2008.01.015
    1. Rowat BM, Merrill CF, Davis A, South V. A double-blind comparison of granisetron and placebo for the treatment of acute migraine in the emergency department. Cephalalgia. 1991;11(5):207-213. doi:10.1046/j.1468-2982.1991.1105207.x
    1. Salazar G, Fragoso M, Vergez L, Sergio P, Cuello D. Metoclopramide as an analgesic in severe migraine attacks: an open, single-blind, parallel control study. Recent Pat CNS Drug Discov. 2011;6(2):141-145. doi:10.2174/157488911795933947
    1. Shahrami A, Assarzadegan F, Hatamabadi HR, Asgarzadeh M, Sarehbandi B, Asgarzadeh S. Comparison of therapeutic effects of magnesium sulfate vs dexamethasone/metoclopramide on alleviating acute migraine headache. J Emerg Med. 2015;48(1):69-76. doi:10.1016/j.jemermed.2014.06.055
    1. Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology. 2003;60(2):315-321. doi:10.1212/01.WNL.0000042477.63516.B2
    1. Tek DS, McClellan DS, Olshaker JS, Allen CL, Arthur DC. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990;19(10):1083-1087. doi:10.1016/S0196-0644(05)81508-2
    1. Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003;41(6):847-853. doi:10.1067/mem.2003.195
    1. Kandil M, Jaber S, Desai D, et al. . MAGraine: Magnesium compared to conventional therapy for treatment of migraines. Am J Emerg Med. 2021;39:28-33.
    1. Motamed H, Mozafari J, Porozan S, Sasani M. Magnesium sulfate and acute migraine: a randomized clinical trial. Ann Clin Anal Med. 2020;11(5):369-373.
    1. Aurora SK, Silberstein SD, Kori SH, et al. . MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51(4):507-517. doi:10.1111/j.1526-4610.2011.01869.x
    1. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache. 2009;49(6):826-837. doi:10.1111/j.1526-4610.2009.01453.x
    1. Bell R, Montoya D, Shuaib A, Lee MA. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med. 1990;19(10):1079-1082. doi:10.1016/S0196-0644(05)81507-0
    1. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26(4):168-171. doi:10.1111/j.1526-4610.1986.hed2604168.x
    1. Diener H-C, Jansen J-P, Reches A, Pascual J, Pitei D, Steiner TJ; Eletriptan and Cafergot Comparative Study Group . Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol. 2002;47(2):99-107. doi:10.1159/000047960
    1. Friedman AP, Di Serio FJ, Hwang DS. Symptomatic relief of migraine: multicenter comparison of Cafergot P-B, Cafergot, and placebo. Clin Ther. 1989;11(1):170-182.
    1. Gallagher RM; Dihydroergotamine Working Group . Acute treatment of migraine with dihydroergotamine nasal spray. Arch Neurol. 1996;53(12):1285-1291. doi:10.1001/archneur.1996.00550120097022
    1. Hakkarainen H, Allonen H. Ergotamine vs metoclopramide vs their combination in acute migraine attacks. Headache. 1982;22(1):10-12. doi:10.1111/j.1526-4610.1982.hed2201010.x
    1. Kangasniemi P, Kaaja R. Ketoprofen and ergotamine in acute migraine. J Intern Med. 1992;231(5):551-554. doi:10.1111/j.1365-2796.1992.tb00973.x
    1. Rapoport A, Sheftell F, Couch J, et al. ; Dihydroergotamine Nasal Spray Multicenter Investigators . Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache. 1995;35(4):177-184. doi:10.1111/j.1526-4610.1995.hed3504177.x
    1. Ryan RE. Double-blind clinical evaluation of the efficacy and safety of ergostine-caffeine, ergotamine-caffeine, and placebo in migraine headache. Headache. 1970;9(4):212-220. doi:10.1111/j.1526-4610.1970.hed0904212.x
    1. Sharma S, Prasad A, Nehru R, et al. . Efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine. Headache. 2002;42(9):896-902. doi:10.1046/j.1526-4610.2002.02210.x
    1. Treves TA, Kuritzky A, Hering R, Korczyn AD. Dihydroergotamine nasal spray in the treatment of acute migraine. Headache. 1998;38(8):614-617. doi:10.1046/j.1526-4610.1998.3808614.x
    1. Tulunay FC, Karan O, Aydin N, Culcuoglu A, Guvener A. Dihydroergotamine nasal spray during migraine attacks: a double-blind crossover study with placebo. Cephalalgia. 1987;7(2):131-133. doi:10.1046/j.1468-2982.1987.0702131.x
    1. Ziegler D, Ford R, Kriegler J, et al. . Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44(3 pt 1):447-453. doi:10.1212/WNL.44.3_Part_1.447
    1. Alemdar M, Pekdemir M, Selekler HM. Single-dose intravenous tramadol for acute migraine pain in adults: a single-blind, prospective, randomized, placebo-controlled clinical trial. Clin Ther. 2007;29(7):1441-1447. doi:10.1016/j.clinthera.2007.07.017
    1. Boureau F, Joubert JM, Lasserre V, Prum B, Delecoeuillerie G. Double-blind comparison of an acetaminophen 400 mg–codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994;14(2):156-161. doi:10.1046/j.1468-2982.1994.1402156.x
    1. Carleton SC, Shesser RF, Pietrzak MP, et al. . Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med. 1998;32(2):129-138. doi:10.1016/S0196-0644(98)70126-X
    1. Freitag FG. The acute treatment of migraine with transnasal butorphanol (TNB). Headache Q. 1993;4(suppl 3):22-28.
    1. Friedman BW, Irizarry E, Solorzano C, et al. . Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology. 2017;89(20):2075-2082. doi:10.1212/WNL.0000000000004642
    1. Hoffert MJ, Couch JR, Diamond S, et al. . Transnasal butorphanol in the treatment of acute migraine. Headache. 1995;35(2):65-69. doi:10.1111/j.1526-4610.1995.hed3502065.x
    1. Klapper JA, Stanton J. Current emergency treatment of severe migraine headaches. Headache. 1993;33(10):560-562. doi:10.1111/j.1526-4610.1993.hed3310560.x
    1. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med. 1989;18(4):360-365. doi:10.1016/S0196-0644(89)80570-0
    1. Richman PB, Allegra J, Eskin B, et al. . A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache. Am J Emerg Med. 2002;20(1):39-42. doi:10.1053/ajem.2002.30007
    1. Scherl ER, Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache. 1995;35(5):256-259. doi:10.1111/j.1526-4610.1995.hed3505256.x
    1. Silberstein SD, Freitag FG, Rozen TD, et al. ; CAPSS-223 Investigators . Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache. 2005;45(10):1317-1327. doi:10.1111/j.1526-4610.2005.00264.x
    1. Stiell IG, Dufour DG, Moher D, Yen M, Beilby WJ, Smith NA. Methotrimeprazine versus meperidine and dimenhydrinate in the treatment of severe migraine: a randomized, controlled trial. Ann Emerg Med. 1991;20(11):1201-1205. doi:10.1016/S0196-0644(05)81471-4
    1. Taheraghdam AA, Amiri H, Shojaan H, Shamsvahdati S, Houshyar Y. Intravenous dexamethasone versus morphine in relieving of acute migraine headache. Pak J Biol Sci. 2011;14(12):682-687. doi:10.3923/pjbs.2011.682.687
    1. Borhani Haghighi A, Motazedian S, Rezaii R, et al. . Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. Int J Clin Pract. 2010;64(4):451-456. doi:10.1111/j.1742-1241.2009.02215.x
    1. Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial. Cephalalgia. 2019;39(1):3-14. doi:10.1177/0333102418811573
    1. Farahmand S, Shafazand S, Alinia E, Bagheri-Hariri S, Baratloo A. Pain management using acupuncture method in migraine headache patients: a single blinded randomized clinical trial. Anesth Pain Med. 2018;8(6):e81688. doi:10.5812/aapm.81688
    1. Fuglsang CH, Johansen T, Kaila K, Kasch H, Bach FW. Treatment of acute migraine by a partial rebreathing device: a randomized controlled pilot study. Cephalalgia. 2018;38(10):1632-1643. doi:10.1177/0333102418797285
    1. Korucu O, Dagar S, Çorbacioglu SK, Emektar E, Cevik Y. The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments. Acta Neurol Scand. 2018;138(3):212-218. doi:10.1111/ane.12952
    1. Li Y, Liang F, Yang X, et al. . Acupuncture for treating acute attacks of migraine: a randomized controlled trial. Headache. 2009;49(6):805-816. doi:10.1111/j.1526-4610.2009.01424.x
    1. Lipton RB, Dodick DW, Silberstein SD, et al. . Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373-380. doi:10.1016/S1474-4422(10)70054-5
    1. Marcus SV. Phase 1 of integrated EMDR: an abortive treatment for migraine headaches. J EMDR Pract Res. 2008;2(1):15-25. doi:10.1891/1933-3196.2.1.15
    1. Niazi M, Hashempur MH, Taghizadeh M, Heydari M, Shariat A. Efficacy of topical rose (Rosa damascena Mill.) oil for migraine headache: a randomized double-blinded placebo-controlled cross-over trial. Complement Ther Med. 2017;34:35-41. doi:10.1016/j.ctim.2017.07.009
    1. Sasannejad P, Saeedi M, Shoeibi A, Gorji A, Abbasi M, Foroughipour M. Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial. Eur Neurol. 2012;67(5):288-291. doi:10.1159/000335249
    1. Tassorelli C, Grazzi L, de Tommaso M, et al. ; PRESTO Study Group . Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology. 2018;91(4):e364-e373. doi:10.1212/WNL.0000000000005857
    1. Triner WR, Bartfield JM, Birdwell M, Raccio-Robak N. Nitrous oxide for the treatment of acute migraine headache. Am J Emerg Med. 1999;17(3):252-254. doi:10.1016/S0735-6757(99)90118-3
    1. Wang L-P, Zhang X-Z, Guo J, et al. . Efficacy of acupuncture for acute migraine attack: a multicenter single blinded, randomized controlled trial. Pain Med. 2012;13(5):623-630. doi:10.1111/j.1526-4637.2012.01376.x
    1. Yang J, Zeng F, Feng Y, et al. . A PET-CT study on the specificity of acupoints through acupuncture treatment in migraine patients. BMC Complement Altern Med. 2012;12:123. doi:10.1186/1472-6882-12-123
    1. Yarnitsky D, Dodick DW, Grosberg BM, et al. . Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache. 2019;59(8):1240-1252. doi:10.1111/head.13551
    1. Yarnitsky D, Volokh L, Ironi A, et al. . Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017;88(13):1250-1255. doi:10.1212/WNL.0000000000003760
    1. Zargaran A, Borhani-Haghighi A, Salehi-Marzijarani M, et al. . Evaluation of the effect of topical chamomile (Matricaria chamomilla L.) oleogel as pain relief in migraine without aura: a randomized, double-blind, placebo-controlled, crossover study. Neurol Sci. 2018;39(8):1345-1353. doi:10.1007/s10072-018-3415-1
    1. Hokenek NM, Erdogan MO, Hokenek UD, Algin A, Tekyol D, Seyhan AU. Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: a randomize controlled trial. Am J Emerg Med. 2021;39:80-85. doi:10.1016/j.ajem.2020.01.024
    1. Antal A, Bischoff R, Stephani C, et al. . Low intensity, transcranial, alternating current stimulation reduces migraine attack burden in a home application set-up: a double-blinded, randomized feasibility study. Brain Sci. 2020;10(11):21. doi:10.3390/brainsci10110888
    1. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi:10.1111/head.12499
    1. Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017;57(10):1507-1521. doi:10.1111/head.13179
    1. Buse DC, Reed ML, Fanning KM, Kurth T, Lipton RB. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2017;57(1):31-44. doi:10.1111/head.12962
    1. Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S. How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine. Headache. 2016;56(7):1194-1200. doi:10.1111/head.12870
    1. Shapiro RE, Hochstetler HM, Dennehy EB, et al. . Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20(1):90. doi:10.1186/s10194-019-1044-6
    1. Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs: lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):E1180. doi:10.3390/pharmaceutics12121180
    1. Pearlman EM, Wilbraham D, Dennehy EB, et al. . Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol. 2020;35(5):e2732. doi:10.1002/hup.2732
    1. Nir R-R, Yarnitsky D. Conditioned pain modulation. Curr Opin Support Palliat Care. 2015;9(2):131-137. doi:10.1097/SPC.0000000000000126
    1. Lipton RB, Schwedt TJ, Friedman BW, et al. . Demographics, headache characteristics, and other factors associated with opioid use in people with migraine: results from the CaMEO study. Neurology. 2019;92:S59.006.
    1. Lipton RB, Araujo AB, Nicholson RA, et al. Patterns of diagnosis, consultation, and treatment of migraine in the US: results of the OVERCOME Study. Presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA.
    1. Ashina S, Foster SA, Nicholson RA, et al. Opioid use among people with migraine: results of the OVERCOME study. Presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA.
    1. Molina KC, Fairman KA, Sclar DA. Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits. Drug Healthc Patient Saf. 2018;10:37-43. doi:10.2147/DHPS.S151073
    1. Bonafede M, Wilson K, Xue F. Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia. 2019;39(9):1086-1098. doi:10.1177/0333102419835465
    1. Connelly M, Glynn EF, Hoffman MA, Bickel J. Rates and predictors of using opioids in the emergency department to treat migraine in adolescents and young adults. Pediatr Emerg Care. 2019. doi:10.1097/PEC.0000000000001851
    1. Vinson DR, Hurtado TR, Vandenberg JT, Banwart L. Variations among emergency departments in the treatment of benign headache. Ann Emerg Med. 2003;41(1):90-97. doi:10.1067/mem.2003.24
    1. Katsarava Z, Schneeweiss S, Kurth T, et al. . Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62(5):788-790. doi:10.1212/01.WNL.0000113747.18760.D2
    1. Langemark M, Olesen J. Drug abuse in migraine patients. Pain. 1984;19(1):81-86. doi:10.1016/0304-3959(84)90067-8
    1. Salomone JA III, Thomas RW, Althoff JR, Watson WA. An evaluation of the role of the ED in the management of migraine headaches. Am J Emerg Med. 1994;12(2):134-137. doi:10.1016/0735-6757(94)90231-3

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever